Division of Urogynecology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Obstet Gynecol. 2020 May;135(5):1084-1090. doi: 10.1097/AOG.0000000000003805.
To compare temporal trends of urogynecologic mesh medical device reports with sentinel U.S. Food and Drug Administration (FDA) notices and to examine all linked reports of patient death.
The Reed Tech Navigator is an online tool used to extract and analyze data in the Manufacturer and User Facility Device Experience database. We used FDA product codes to search for reports of synthetic mesh for stress urinary incontinence (SUI) and pelvic organ prolapse (POP). Reports with "death" listed as a patient event were queried further.
There were 43,970 medical device reports involving urogynecologic mesh reported to the FDA between August 2000 and January 2019, with most occurring after the 2011 FDA communication (n=43,018, 97.8%). Of these medical device reports, 64.6% (n=28,422) were for SUI products, 27.0% (n=11,876) were for transvaginal POP products, and 8.4% (n=3,672) were for transabdominal POP products. Peak reporting occurred in 2013, which corresponded with the first major plaintiff verdicts and class action vaginal mesh settlement. There were 645 (1.5%) medical device reports of death, with 49.3% (n=318) having no cause of death identified. Only four (0.6%) could be directly attributed to the initial surgery.
Since 2011, urogynecologic mesh has been the focus of thousands of medical device reports annually, although the data submitted are often incomplete. Few reported deaths are directly attributable to mesh products, and the majority lack sufficient information to draw causal conclusions. A high-quality registry is necessary to improve our understanding of the patient effect from urogynecologic mesh products.
比较尿妇科网片医疗器械报告的时间趋势与美国食品和药物管理局(FDA)的警戒通知,并检查所有与患者死亡相关的报告。
ReedTechNavigator 是一种在线工具,用于从制造商和用户设施设备体验数据库中提取和分析数据。我们使用 FDA 产品代码搜索用于治疗压力性尿失禁(SUI)和盆腔器官脱垂(POP)的合成网片的报告。进一步查询了将“死亡”列为患者事件的报告。
2000 年 8 月至 2019 年 1 月,FDA 共收到 43970 份涉及尿妇科网片的医疗器械报告,其中大部分发生在 2011 年 FDA 沟通之后(n=43018,97.8%)。在这些医疗器械报告中,64.6%(n=28422)用于治疗 SUI 产品,27.0%(n=11876)用于经阴道 POP 产品,8.4%(n=3672)用于经腹 POP 产品。报告高峰发生在 2013 年,这与第一批主要原告判决和阴道网片集体诉讼和解相吻合。有 645 份(1.5%)医疗器械报告死亡,其中 49.3%(n=318)未确定死因。只有 4 份(0.6%)可直接归因于初始手术。
自 2011 年以来,尿妇科网片每年都是数千份医疗器械报告的焦点,尽管提交的数据往往不完整。很少有报告的死亡直接归因于网片产品,而且大多数报告缺乏足够的信息来得出因果结论。建立高质量的登记制度对于提高我们对尿妇科网片产品对患者影响的理解是必要的。